The latest voluntary withdrawal stemming from the US regulator’s review of accelerated approvals is Bristol Myers Squibb’s (NYSE: BMY) nod for Opdivo (nivolumab) in liver cancer.
The decision follows an earlier withdrawal for the checkpoint blocker, in late 2020, in small cell lung cancer (SCLC).
Several other drugmakers have been affected by the US Food and Drug Administration’s decision to take a fresh look at accelerated approvals which have not met post-marketing requirements.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze